Quantapore Inc. announced the appointment of Dr. Alex Dickinson and Robert Proulx to the Board of Directors. Both Directors bring a wealth of experience in the development and commercialization of new technologies and operating high-growth businesses. Alex and Bob join Dr. Martin Huber and Dr. Sascha Dennstedt, Quantapore’s co-founders as well as Feng Deng of Northern Light Venture Capital on the Board.

Alex Dickinson has over 25 years of experience founding and leading both startups and new businesses in large companies. He is the Founder and Executive Chairman of ChromaCode, a molecular diagnostics company and a member of the board of directors of PRAH Health Sciences (NASDAQ: PRAH), a leading contract research organization. Previously, he was a Senior Vice President at Illumina, Inc. where he developed precision medicine programs for national healthcare systems and led the team that built Illumina’s cloud-based sequencing informatics platform, BaseSpace. Prior to joining Illumina, Alex was founder and CEO of Helixis, a molecular diagnostics company that was acquired by Illumina in 2010. Earlier, Alex was the founder and CEO of Luxtera, now the world’s leading provider of silicon photonics products. He holds a Ph.D. from the University of Adelaide, Australia, and an MBA from Columbia University in New York.

“I’ve had the opportunity to look into many novel sequencing technologies and Quantapore’s approach is the first I’ve seen that can really shake up the industry. By combining the long-read capability of nanopores with the accuracy and scalability of optical base detection, Quantapore’s products will achieve an ease of use and scalability that can’t be matched by other technologies. I’m thrilled to be helping the company with this next stage.”

Robert Proulx is a veteran business executive with more than 25 years of leadership experience for both private and public companies in the life science and diagnostic device markets. Currently Bob is the Executive Chairman and CEO of Imagion Biosystems, a medical imaging company which is dedicated to providing tools to find and eliminate cancer. Previously Bob was the President of Silicon Biosystems, where he led the commercial introduction of an image-based CTC liquid biopsy technology which was acquired by the Menarini Group in 2013. Bob has held executive positions at Nanogen, Gene Logic, IGEN and Packard Bioscience. He holds an M.A. and B.A. from The State University of New York at Albany and an Executive MBA from the Penn State Smeal College of Business.

“Most products in the life science and healthcare space are incremental improvements over current methods, so it is very exciting to be invited to join Quantapore where there is a real opportunity to change the dynamics in one of the industry’s key technology segments.”

“Quantapore is fortunate and honored to have Alex and Bob serve on our Board,” said Quantapore’s CEO Dr. Martin Huber. “Both have amazing track records taking disruptive technologies to market by executing effective strategies and securing the capital to do so. I look forward to benefitting from their guidance as Quantapore accelerates its journey toward becoming the leader in genomic sequencing”

About Quantapore Incorporated

Quantapore Inc. is a biotechnology company focused on the development and commercialization of an ultra-low-cost, high-throughput DNA sequencing platform. Based in Menlo Park, CA, the company was founded in 2009 and is well on its way to the commercialization of its novel sequencing platform. The combination of low cost, long reads, simple workflow and fast sample to result turnaround time holds the promise to make Quantapore Inc. one of the world’s leading sequencing system providers.

www.quantapore.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180723005758/en/